Health Studies MN

Within 


Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

604 Study Matches

Sorting by: Relevance Distance

CureGN: Cure Glomerulonephropathy Network

A Registry and Biospecimen Collection to Advance the Diagnosis and Care of Patients with Glomerular Diseases

Fernando Fervenza
All
Not specified
This study is NOT accepting healthy volunteers
2020-300830-P01-RST
19-012484
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria

  • Diagnosis of MCD, FSGS, MN, or IgAN on first diagnostic kidney biopsy, per specified pathology definitions.
  • First diagnostic kidney biopsy within 5 years of study enrollment.
  • Access to first kidney biopsy report and/or slides.
  • All ages.
  • Willing to comply with study requirements, including intention to fully participate in protocol-specified follow-up at a clinical study site.
  • Informed consent and, where age appropriate, informed assent.

 Exclusion Criteria

  • ESKD, defined as chronic dialysis or kidney transplant.
  • Institutionalized.
  • Solid organ or bone marrow transplant recipient at time of first kidney biopsy.
  • Diagnosis of any of the following at the time of first diagnostic kidney biopsy:
    • Diabetes mellitus;
    • Histopathologic findings of diabetic glomerulosclerosis;
    • Systemic lupus erythematosus;
    • HIV infection;
    • Active malignancy, except for non-melanoma skin cancer;
    • Active Hepatitis B or C infection, defined as positive viral load.
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

A Phase IIB Randomized Trial of Oral Tamoxifen vs. Topical 4-hydroxytamoxifen Gel vs. Control in Women with Atypical Hyperplasia or Lobular Carcinoma In Situ

A Study to Evaluate Oral Tamoxifen vs. TamGel vs. Control in Women with Atypical Hyperplasia or Lobular Carcinoma In Situ

Amy Degnim
Female
18 years to 80 years old
Phase 2
This study is NOT accepting healthy volunteers
2020-300972-P01-RST
19-011444
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:


- Willing to return to enrolling institution for follow-up

- Willing to complete required testing

- Ability to complete questionnaire by themselves or with assistance

- Female (sex that was assigned at birth)

- Ipsilateral intact breast with histology confirmation of atypical ductal or lobular
hyperplasia, or LCIS, within the last 12 months, whether surgically excised or not.

- Eastern Cooperative Oncology Group (ECOG) performance status ≤1

- Willingness to agree to use ONE effective form of birth control (abstinence is not an
allowed method) prior to study entry and for the duration of study participation, and
for 2 months following the last dose of study medications. Effective birth control
methods are: copper IUD [intrauterine device], diaphragm/cervical cap/shield,
spermicide, contraceptive sponge, condoms. Women of childbearing potential must have a
negative pregnancy test within five days before starting study medications. Should a
participant become pregnant or suspect she is pregnant while participating in this
study; the participant should inform the study physician immediately.

- Willingness to avoid exposing breast skin to natural or artificial sunlight (i.e.
tanning beds) for the duration of the study.

- Participants must have acceptable organ and marrow function as defined below within 30
days of randomization: judged by treating physician's evaluation of baseline
laboratory data.

- Negative urine pregnancy test, if of childbearing potential. and / or FSH to verify
menopausal status.


Exclusion Criteria:


- Clinically suspicious mass/lesions Breast cancer in the past 5 years.

- Prior thromboembolism within last 5 years (history of varicose veins and superficial
phlebitis is allowed) Current pregnancy or lactation History of other prior breast
cancer-specific therapy within the previous 2 years (chemotherapy, anti-HER2 agents,
endocrine agents, everolimus, CDK4-6 inhibitors).

- Cytotoxic chemotherapy for any indication in last 2 years.

- Prior use of SERMS or AIs including tamoxifen, raloxifene, anastrozole, letrozole, or
exemestane for prevention or therapy within 5 years.

- Exogenous sex steroid, including oral contraceptive pill use within 1 month prior to
research core needle biopsy (CNB).

- Use of vaginally administered estrogens and hormone coated IUD such as Mirena is
permitted History of any prior ipsilateral breast radiotherapy. Previous unilateral
radiation of the contralateral side is allowed.

- Skin lesions on the breast that disrupt the stratum corneum (eg eczema, ulceration).

- History of endometrial neoplasia

- Current smoker. Cessation for at least 6 weeks

- Current users of potent inhibitors of tamoxifen metabolism. The potent inhibitors of
tamoxifen metabolism are: bupropion, cinacalcet, fluoxetine, paroxetine, quinidine.

- Participants may not be receiving any other investigational agents within 90 days of
enrollment or during this study.

- History of allergic reactions to tamoxifen.

- Uncontrolled intercurrent illness that in the judgement of the treating physician
would make them unsuitable for study participation

- Anticoagulation meds and clinical concern for discontinuing meds for study research
biopsy.

- Identification of a clinically suspicious mass on examination.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 10/12/22. Questions regarding updates should be directed to the study team contact.

Drug
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Therapeutic and Side Effects of Invasive and Noninvasive Brain Stimulation

A Study to Evaluate Therapeutic and Side Effects of Brain Stimulation

Brian Lundstrom
All
1 years to 99 years old
This study is NOT accepting healthy volunteers
2020-302381-H01-RST
19-002063
Show full eligibility criteria
Hide eligibility criteria

Key Inclusion Criteria:

  • Patients that receive brain stimulation for evaluation or treatment of neurological diseases including intractable epilepsy, chronic pain syndromes and brain tumors.

Key Exclusion Criteria

  • Patients that do not receive brain stimulation for evaluation or treatment of neurological diseases including intractable epilepsy, chronic pain syndromes, and brain tumors.

     

I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Insomnia in patients with metastatic non small cell lung cancer.

Metastatic Non-Small Cell Lung Cancer Insomnia

Konstantinos Leventakos
All
18 years and over
This study is NOT accepting healthy volunteers
2022-309377-P01-RST
19-001466
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Have a diagnosis of metastatic non small cell lung cancer.
  • Undergoing 1st, 2nd or 3rd line of treatment or are in maintenance therapy.
  • Subjects will be limited to older than 18 years old at the time of diagnosis.


Exclusion Criteria:
 

  • Have advanced terminal cancer, severe depression, or other psychiatric disorder or a sleep disorder other than insomnia (sleep apnea, restless leg syndrome, sleep related disorder of breathing).
  • Regular use of psychotropic medication other than hypnotics (e.g., antidepressants) per chart review.

Eligibility last updated 9/2/22. Questions regarding updates should be directed to the study team contact.

I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN